Clinical trials: Beta-cell Function
Type 1 Diabetes
The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)
The primary aim of this pilot study is to test whether gluten-free diet (GFD) instituted in children shortly after onset of Type 1 Diabetes (T1D) can decelerate the decline in beta cell function as compared to age matched…
- Trial name
- NCT02867436
- Testing
- Gluten-free diet
- Where
- 2 sites in Czechia
- Volunteers
- 45 people
- Sponsor
- University Hospital, Motol
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the…
- Conditions
- Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
- Trial name
- EXTEND (NCT02293837)
- Testing
- Tocilizumab (TCZ), Standard of Care
- Where
- 19 sites in United States, Australia
- Volunteers
- 136 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
- Trial name
- TN09 (NCT00505375)
- Testing
- CTLA-4 Ig
- Where
- 13 sites in United States, Canada
- Volunteers
- 112 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes Mellitus
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
- Trial name
- NCT00232583
- Testing
- Metformin, Insulin, Metfomin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Texas Southwestern Medical Center
Healthy
DPP4 Inhibition & Beta Cell Function
This study is being done to determine the role of a hormone, glucagon-like peptide 1 (GLP-1), on insulin secretion and to study how GLP-1 works in in diabetic individuals as compared to non-diabetic individuals, under fasting…
- Trial name
- NCT02683187
- Testing
- Active Comparator: Sitagliptin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Diabetes Mellitus, Type 1
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
The drug Alpha-1 Antitrypsin (AAT, Aralast NP) is being tested in this study as an anti-inflammatory drug (a medication that decreases inflammation, which is part of the body's normal ability to fight infection and respond to…
- Trial name
- RETAIN (NCT01183468)
- Testing
- Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
- Where
- 15 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 2 Diabetes Mellitus
Beta-Cell Function and Sitagliptin Trial (BEST)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily…
- Trial name
- BEST (NCT00420511)
- Testing
- Sitagliptin, metformin
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Type 1 Diabetes
Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes
This project is designed to study the role of vitamin D supplementation on the honeymoon phase of type 1 diabetes in children who are on standardized insulin treatment.
- Trial name
- PCR (NCT03046927)
- Testing
- Ergocalciferol
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Benjamin U. Nwosu, MD
Type 2 Diabetes Mellitus
Study of the Durability of Glycemic Control With Nateglinide
This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.
- Trial name
- NCT00858013
- Testing
- Nateglinide, Glimepiride
- Where
- 7 sites in South Korea
- Volunteers
- 88 people
- Sponsor
- Ajou University School of Medicine
Insulin Sensitivity
Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery
The purpose of this study is to determine whether preload of carbohydrate or water before elective hip replacement improve insulin sensitivity and or beta cell function in human.
- Trial name
- NCT01774084
- Testing
- Experimental: PreOp, NutriciaNordica AB
- Where
- 2 sites in Sweden
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Type 1 Diabetes Mellitus
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin…
- Trial name
- NCT02372253
- Testing
- Verapamil
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Type 2 Diabetes, Oxidative Stress
Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
Insulin is secreted by cells in the pancreas called beta-cells. Beta-cell dysfunction is a critical feature of type 2 diabetes (T2DM).
- Trial name
- NCT01394510
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Utzschneider, Kristina, M.D.
Type 1 Diabetes
Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
This is an extension study to evaluate the safety and tolerability of long-term treatment with DiaPep277® and to determine the long-term treatment effect of DiaPep277® on parameters of metabolic control and on preservation of…
- Trial name
- DIA-AID 2 (NCT01898286)
- Testing
- DiaPep277®
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Andromeda Biotech Ltd.
Impaired Glucose Tolerance, Oxidative Stress
Effect of Dietary Glycemic Index on Beta-cell Function
The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for…
- Conditions
- Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
- Trial name
- GIdiet (NCT01386645)
- Testing
- low glycemic index (LGI) diet, high glycemic index diet plus N-acetylcysteine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research